Navigation Links
AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Date:4/1/2008

QUEBEC CITY and MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, and Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that, on March 31, 2008, they completed the transactions under their previously announced purchase and sale agreement with respect to all rights related to the manufacture, production, distribution, marketing, sale and/or use of miltefosine. The aggregate purchase price for the transaction was Cdn$9.125 million payable in cash, subject to certain post-closing purchase price adjustments.

About miltefosine

Miltefosine is a phosphocholine analogue currently marketed under the brand name Impavido(R), the first oral drug for the treatment of visceral and cutaneous leishmaniasis. Impavido(R) has been proven to be highly effective and less toxic than currently available treatments. Other currently available treatments are liposomal amphotericin (Ambisome(R)) and Paromomycin.

About leishmaniasis

Leishmaniasis is an infectious disease transmitted by the bite of the phlebotomine sandfly. The cutaneous form of the disease normally produces skin ulcers on the exposed parts of the body such as the face, arms and legs. The visceral form - also known as kala azar - is characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (occasionally serious).

According to the World Health Organization, the disease is endemic in 88 countries with nearly 350 million people at risk. If untreated, visceral leishmaniasis can result in death within 6 months to 2 years. There are more than one millio
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... (Amex: ETC ) ("ETC" or the "Company") ... additional BARA-MED(R) XD,Monoplace Hyperbaric Chambers to Comprehensive Healthcare ... company who focuses,solely on initiating and operating Wound ... total of five (5) BARA-MED(R) XD chambers,from ETC ...
... Oct. 9 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. ... "the,Company"), a leading provider in the health ... manufacture and distribution of nutritional,food products, dietary ... People,s,Republic of China ("PRC"), today announced that ...
... from around the world join forces in the Global Fight ... on the parasite Plasmodium falciparum, which is responsible for the ... of the same genus which, despite producing a milder form ... Plasmodium vivax , to which is attributed almost 300 ...
Cached Biology Technology:Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions 2Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions 3Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions 4China Yingxia International, Inc. Announces $2 Million Share Repurchase Program 2China Yingxia International, Inc. Announces $2 Million Share Repurchase Program 3The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria 2The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria 3
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
(Date:12/24/2014)... its launch in December 2014, the 1U™ app ... trying to remember their usernames and passwords through replacing the ... To assist people who have struggled to remember usernames and ... and focuses on redefining identity, announced today that it is ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... get outdoors and help track the effects of climate ... The USA-National Phenology Network (USA-NPN), a consortium of government, ... built on volunteer observations of flowering, fruiting and other ... use these observations to track effects of climate change ...
... 3,500 people are affected with retinitis pigmentosa (RP), a ... to blindness. Now, a University of Missouri researcher has ... two different forms of RP. This discovery will help ... and humans. "The same genetic ...
... March 4, 2009 The incidence of pneumothorax (PTX), or ... trauma has been reported to range from 13 50 ... In people, PTX is reported to be the most ... Thoracic ultrasound has been infrequently used as a non-invasive, point-of-care ...
Cached Biology News:Taking the pulse of our planet 2Cats' eye diseases genetically linked to diseases in humans 2Novel veterinary procedure detecting life-threatening injuries touted 2
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
... Antigen Afinity Purified Tyrosine ... polyclonal antibody was raised against ... acids residues surrounding the phospho-Ser40 ... The antibody was purified by ...
Biology Products: